Quantcast

Latest Daiichi Sankyo Stories

2014-01-29 16:28:33

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ztm9m5/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" [http://www.researchandmarkets.com/research/ztm9m5/antibodydrug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report entitled 'Antibody-Drug Conjugates 2014 - A Business,...

2014-01-28 08:29:50

PLANTATION, Fla., Jan. 28, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer. Dr. Richard Scheyer Dr. Richard Scheyer has 30 years of...

2014-01-20 12:23:08

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 Summary GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes...

2014-01-08 12:30:25

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and PARSIPPANY, N.J., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSA(TM) (edoxaban) Tablets has been submitted to the U.S. Food...

2014-01-08 08:28:54

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas. Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets....

2014-01-07 12:28:27

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related